vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and Strawberry Fields REIT, Inc. (STRW). Click either name above to swap in a different company.

Strawberry Fields REIT, Inc. is the larger business by last-quarter revenue ($40.1M vs $37.2M, roughly 1.1× GYRE THERAPEUTICS, INC.). Strawberry Fields REIT, Inc. runs the higher net margin — 5.0% vs -3.7%, a 8.7% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 31.5%). Over the past eight quarters, Strawberry Fields REIT, Inc.'s revenue compounded faster (20.0% CAGR vs 17.0%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

Strawberry Fields REIT, Inc. is a real estate investment trust focused on healthcare-related real estate assets. It owns, operates and manages skilled nursing facilities, senior living communities, and medical office buildings, primarily serving markets across the United States for healthcare providers and elderly care operators.

GYRE vs STRW — Head-to-Head

Bigger by revenue
STRW
STRW
1.1× larger
STRW
$40.1M
$37.2M
GYRE
Growing faster (revenue YoY)
GYRE
GYRE
+1.9% gap
GYRE
33.4%
31.5%
STRW
Higher net margin
STRW
STRW
8.7% more per $
STRW
5.0%
-3.7%
GYRE
Faster 2-yr revenue CAGR
STRW
STRW
Annualised
STRW
20.0%
17.0%
GYRE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GYRE
GYRE
STRW
STRW
Revenue
$37.2M
$40.1M
Net Profit
$-1.4M
$2.0M
Gross Margin
95.3%
Operating Margin
0.3%
52.4%
Net Margin
-3.7%
5.0%
Revenue YoY
33.4%
31.5%
Net Profit YoY
-340.1%
37.6%
EPS (diluted)
$-0.01
$0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
STRW
STRW
Q4 25
$37.2M
$40.1M
Q3 25
$30.6M
$39.7M
Q2 25
$26.8M
$37.9M
Q1 25
$22.1M
$37.3M
Q4 24
$27.9M
$30.5M
Q3 24
$25.5M
$29.5M
Q2 24
$25.2M
$29.3M
Q1 24
$27.2M
$27.8M
Net Profit
GYRE
GYRE
STRW
STRW
Q4 25
$-1.4M
$2.0M
Q3 25
$5.9M
$2.0M
Q2 25
$1.6M
$2.0M
Q1 25
$3.7M
$1.6M
Q4 24
$569.0K
$1.5M
Q3 24
$2.9M
$944.0K
Q2 24
$4.5M
$938.0K
Q1 24
$9.9M
$746.0K
Gross Margin
GYRE
GYRE
STRW
STRW
Q4 25
95.3%
Q3 25
94.7%
Q2 25
95.7%
Q1 25
95.9%
Q4 24
95.8%
Q3 24
96.2%
Q2 24
96.9%
Q1 24
96.4%
Operating Margin
GYRE
GYRE
STRW
STRW
Q4 25
0.3%
52.4%
Q3 25
22.7%
56.6%
Q2 25
8.1%
54.5%
Q1 25
10.3%
54.1%
Q4 24
2.4%
51.5%
Q3 24
16.6%
54.4%
Q2 24
12.7%
52.3%
Q1 24
29.7%
51.3%
Net Margin
GYRE
GYRE
STRW
STRW
Q4 25
-3.7%
5.0%
Q3 25
19.4%
5.1%
Q2 25
5.9%
5.2%
Q1 25
16.9%
4.2%
Q4 24
2.0%
4.8%
Q3 24
11.2%
3.2%
Q2 24
18.0%
3.2%
Q1 24
36.6%
2.7%
EPS (diluted)
GYRE
GYRE
STRW
STRW
Q4 25
$-0.01
$0.15
Q3 25
$0.03
$0.16
Q2 25
$0.00
$0.16
Q1 25
$0.00
$0.13
Q4 24
$0.00
$0.17
Q3 24
$0.01
$0.14
Q2 24
$0.01
$0.14
Q1 24
$0.03
$0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
STRW
STRW
Cash + ST InvestmentsLiquidity on hand
$52.4M
$31.8M
Total DebtLower is stronger
$794.7M
Stockholders' EquityBook value
$106.0M
$12.1M
Total Assets
$166.1M
$885.2M
Debt / EquityLower = less leverage
65.64×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
STRW
STRW
Q4 25
$52.4M
$31.8M
Q3 25
$60.0M
$19.8M
Q2 25
$54.4M
$96.3M
Q1 25
$29.9M
$42.3M
Q4 24
$26.7M
$48.4M
Q3 24
$25.1M
$29.3M
Q2 24
$25.1M
$16.1M
Q1 24
$37.4M
$15.1M
Total Debt
GYRE
GYRE
STRW
STRW
Q4 25
$794.7M
Q3 25
$779.4M
Q2 25
$794.1M
Q1 25
$715.5M
Q4 24
$673.9M
Q3 24
$584.5M
Q2 24
$555.0M
Q1 24
$560.4M
Stockholders' Equity
GYRE
GYRE
STRW
STRW
Q4 25
$106.0M
$12.1M
Q3 25
$101.9M
$14.2M
Q2 25
$92.0M
$15.5M
Q1 25
$68.1M
$19.6M
Q4 24
$63.3M
$18.2M
Q3 24
$63.2M
$12.6M
Q2 24
$60.4M
$7.4M
Q1 24
$56.6M
$7.5M
Total Assets
GYRE
GYRE
STRW
STRW
Q4 25
$166.1M
$885.2M
Q3 25
$159.4M
$880.6M
Q2 25
$152.6M
$897.3M
Q1 25
$129.8M
$834.8M
Q4 24
$125.4M
$787.6M
Q3 24
$125.2M
$661.5M
Q2 24
$120.9M
$635.9M
Q1 24
$122.0M
$634.9M
Debt / Equity
GYRE
GYRE
STRW
STRW
Q4 25
65.64×
Q3 25
54.70×
Q2 25
51.26×
Q1 25
36.47×
Q4 24
37.09×
Q3 24
46.34×
Q2 24
74.61×
Q1 24
74.81×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
STRW
STRW
Operating Cash FlowLast quarter
$-5.6M
$90.0M
Free Cash FlowOCF − Capex
$-5.8M
FCF MarginFCF / Revenue
-15.5%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
44.62×
TTM Free Cash FlowTrailing 4 quarters
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
STRW
STRW
Q4 25
$-5.6M
$90.0M
Q3 25
$4.7M
$20.7M
Q2 25
$2.1M
$29.8M
Q1 25
$-129.0K
$19.0M
Q4 24
$-2.8M
$59.3M
Q3 24
$1.7M
$11.8M
Q2 24
$-5.5M
$20.6M
Q1 24
$2.9M
$2.1M
Free Cash Flow
GYRE
GYRE
STRW
STRW
Q4 25
$-5.8M
Q3 25
$4.0M
Q2 25
$1.8M
Q1 25
$-251.0K
Q4 24
$-2.8M
Q3 24
$1.0M
Q2 24
$-6.9M
Q1 24
$2.7M
FCF Margin
GYRE
GYRE
STRW
STRW
Q4 25
-15.5%
Q3 25
13.1%
Q2 25
6.8%
Q1 25
-1.1%
Q4 24
-10.1%
Q3 24
4.1%
Q2 24
-27.5%
Q1 24
9.8%
Capex Intensity
GYRE
GYRE
STRW
STRW
Q4 25
0.4%
Q3 25
2.2%
Q2 25
1.0%
Q1 25
0.6%
Q4 24
0.2%
Q3 24
2.7%
Q2 24
5.8%
Q1 24
0.9%
Cash Conversion
GYRE
GYRE
STRW
STRW
Q4 25
44.62×
Q3 25
0.79×
10.26×
Q2 25
1.32×
15.24×
Q1 25
-0.03×
11.97×
Q4 24
-4.85×
40.44×
Q3 24
0.60×
12.53×
Q2 24
-1.21×
21.93×
Q1 24
0.29×
2.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons